Navigation Links
Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Date:12/12/2007

MARIETTA, Ga., Dec. 12 /PRNewswire/ -- Solvay Pharmaceuticals, Inc., announced today that the company will continue to work closely with the U.S. Food and Drug Administration (FDA) to fully address the questions raised by members of the Cardio-Renal Advisory Committee in its meeting to consider tedisamil as a treatment for rapid conversion of recent onset atrial fibrillation to normal sinus rhythm (NSR).

The Committee voted against approval of tedisamil, at this time, requesting that Solvay Pharmaceuticals provides additional information to the Agency. While not binding, the Committee's recommendations will be considered by the FDA in its review of the New Drug Application (NDA) for tedisamil.

"Although we are disappointed with today's vote, we remain committed to working with the FDA to determine appropriate next steps in the review of this drug application," said Laurence Downey, M.D., President and CEO of Solvay Pharmaceuticals, Inc.

The New Drug Application (NDA) for tedisamil was filed with the FDA in December 2006. Following Solvay Pharmaceuticals' submission of additional clinical data amending the NDA for tedisamil, FDA extended the typical 10- month review period. Under this revised timeline, Solvay Pharmaceuticals anticipates action from the FDA on or before January 19, 2008.

About Atrial Fibrillation

Atrial fibrillation (AFib) is an abnormal heart rhythm, known as a cardiac arrhythmia, affecting the upper chambers of the heart (atria). In this condition, the electrical signals in the atria that are responsible for directing the activity of the lower chambers of the heart (ventricles) become unsynchronized, and the ventricles continue pumping, usually irregularly and rapidly. This fast, uncoordinated rhythm prevents the heart from efficiently pumping blood out to the body. Some heart conditions associated with AFib include hypertension, heart failure, and coronary artery disease.

AFib -- the most common clin
'/>"/>

SOURCE Solvay Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
4. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
5. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
6. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
7. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
10. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
11. FDA Advisory Committees Recommend Continued U.S. Marketing Authorization for Trasylol(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... FAIRFAX, Va. , Aug. 21, 2014 /PRNewswire/ ... real-time quality and Manufacturing Intelligence , today ... Intelligence Conference. The event will be held Oct. ... Mile, and is designed to showcase the necessity ... use of metrics and Manufacturing Intelligence to gain ...
(Date:8/21/2014)... 2014 CVS Caremark Corporation (NYSE: CVS ... and consideration payable in connection with its previously announced cash ... for (1) any and all of its 6.250% Senior Notes ... to a maximum amount of its 6.125% Senior Notes due ... due 2017 (collectively, the "Maximum Tender Offer Notes" and together ...
(Date:8/21/2014)... TORONTO , Aug. 21, 2014 /CNW/ - Bedrocan ... appointed three independent members to its Board of ... care experience of the company, a leading licensed ... . Internationally, Bedrocan has 13 years, experience ... patients in seven countries, including Canada. ...
Breaking Medicine Technology:InfinityQS to Host Manufacturing Intelligence Conference in Chicago 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 2CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 3CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 4CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 5CVS Caremark Corporation Announces Early Results of Tender Offers, Pricing, Election of Early Settlement and Increase in the Maximum Tender Offer Amount 6Senior Life Sciences Executives Join Bedrocan as Independent Directors 2Senior Life Sciences Executives Join Bedrocan as Independent Directors 3
... SKILLMAN, N.J., Oct. 1 The Great Comebacks® ... Celebrating its 25th anniversary this year, the ... of adults and young people who have overcome ... , The awards are sponsored by ConvaTec, a ...
... Oct. 1 Echo Therapeutics, Inc. (OTC Bulletin Board: ... needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal ... System for transdermal drug delivery, announced today that Patrick ... present at the 4th Annual JMP Securities Healthcare Conference ...
Cached Medicine Technology:The Great Comebacks(R) Program Announces 2009 Regional Awards Recipients 2The Great Comebacks(R) Program Announces 2009 Regional Awards Recipients 3The Great Comebacks(R) Program Announces 2009 Regional Awards Recipients 4Echo Therapeutics to Present at 4th Annual JMP Securities Healthcare Conference 2
(Date:8/21/2014)... August 21, 2014 Pulmonary Hypertension ... an Education Forum for PH patients and families ... Pulmonary Hypertension Association – the country’s ... ways to prevent and cure pulmonary hypertension (PH) ... the functioning of the heart and can lead ...
(Date:8/21/2014)... August 21, 2014 The City of ... for entertainment and programming for its inaugural “Re:Imagine Garden ... October 12, 2014, from 11 a.m. to 4 p.m., ... all cars and the downtown will be filled with ... by Community Arts Resources (CARS), for all to enjoy. ...
(Date:8/21/2014)... Dennis Thompson HealthDay Reporter ... A combination of therapy and antidepressants appears to best ... study reports. Four out of five people suffering ... full recovery when treated with cognitive therapy plus antidepressant ... combination didn,t work much better than drugs alone in ...
(Date:8/21/2014)... is to focus on her body in terms of ... her as a complete human being with thoughts and ... in the media, how does it affect individual romantic ... Quarterly , a SAGE journal, finds that more objectification ... incidents of sexual pressure and coercion., Researchers Laura R. ...
(Date:8/21/2014)... The world wound care market is expected ... reach USD 18.3 billion by 2019, posting a CAGR ... such growth include governments’ contribution to the development of ... surging ageing population. However, the growth could be restrained ... North America leads the global wound care market, with ...
Breaking Medicine News(10 mins):Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 2Health News:Pulmonary Hypertension Association Goes On the Road to Houston With an Education Forum for PH Patients and Families to Help Fight Rare Lung Disease 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 2Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 3Health News:"Re:Imagine Garden Grove - A Downtown Open Streets Event" 4Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 2Health News:Talk Therapy Plus Meds May Be Best for Severe Depression 3Health News:Objectification in romantic relationships related to sexual pressure and coercion 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3
... from the United Kingdom cured well-established prostate tumors in ... effects. This novel cancer treatment approach encourages the immune ... from toxic chemotherapies and radiation treatments. Such a treatment ... free with fewer side effects than those experienced from ...
... , SATURDAY, June 18 (HealthDay News) -- Whether they ... should never be in close proximity to a running lawn ... a running lawn mower. And children under the age of ... lawn mower or walk-behind mower," Dr. Edwin Harris, pediatric podiatrist ...
... News) -- Last year, more people died than were born ... shows. This trend, known as natural decrease, is the ... in fertility levels. Researchers from the Carsey Institute at the ... are particularly hard hit by natural population decrease, which is ...
... The first three patients to undergo an investigational surgical ... own stem cells continue to do well, reports the ... The "TGI-PVG IDE" clinical trial initiated at UofL ... man-made bypass grafts to better the chances at saving ...
... , FRIDAY, June 17 (HealthDay News) -- ... reveals that doctors may overprescribe antibiotics to patients receiving ... McMaster University in Ontario, Canada, found that patients younger ... are at greatest risk for misuse of the drugs. ...
... News) -- Foster care boosts language development in young children ... looked at more than 100 children who had lived in ... in foster homes when they were about 22 months old, ... groups were compared to about 60 young children who lived ...
Cached Medicine News:Health News:Mayo Clinic researchers use human vaccine to cure prostate cancer in mice 2Health News:Adults Reminded to Keep Kids Away From Lawn Mowers 2Health News:Deaths Exceed Births in 24% of U.S. Communities: Report 2Health News:University of Louisville surgeons perform first prosthetic bypass graft with patient's stem cells at point-of-care 2Health News:University of Louisville surgeons perform first prosthetic bypass graft with patient's stem cells at point-of-care 3Health News:University of Louisville surgeons perform first prosthetic bypass graft with patient's stem cells at point-of-care 4Health News:Docs Overprescribing Antibiotics for Home-Care Patients: Study 2Health News:Language Delays Seen in Kids in Institutions Beyond Age 2 2
... the ProtecPoint Exit Alerting System, instantly ... and assets (e.g. medical equipment), with ... facility. With this form of exit ... savings, operating efficiencies, and overall peace ...
... Context-sensitive medicine is the ability of ... in pre-determined ways based on what is ... the associations a Radianse indoor positioning solution ... and it requires identity, location and time ...
... ability to track the movement of ... assets can be done. VerdaSee's "intellishelvess" ... Continuous cycle counting is possible with ... (RFID) technology makes this possible. VerdaSee ...
Agility has delivered a RFID-enabled mobile asset management program....
Medicine Products: